Clementia Pharmaceuticals (CMTA) Stock Price, News & Analysis

Company Overview

Clementia Pharmaceuticals Inc., a clinical stage biopharmaceutical company, develops treatments for patients suffering from bone disorders and other diseases. Its lead product candidate is palovarotene, an oral small molecule for the treatment of fibrodysplasia ossificans progressive, multiple osteochondromas, dry eye disease, and other diseases is in the Phase 3 MOVE Trial. Clementia Pharmaceuticals Inc. was founded in 2010 and is based in Montreal, Canada.

Key Stats

• Today's Range: $26.28 to $26.69
• 50-Day Range: $26.35 to $26.35
• 52-Week Range: $8.10 to $26.73
• Volume: 716,706 shs
• Average Volume: 145,059 shs
• Market Capitalization: $1.00 billion
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

CMTA Stock Analysis - Frequently Asked Questions

How were Clementia Pharmaceuticals' earnings last quarter?

Clementia Pharmaceuticals Inc. (NASDAQ:CMTA) posted its quarterly earnings data on Wednesday, November, 7th. The company reported ($0.46) EPS for the quarter, missing the consensus estimate of ($0.42) by $0.04.

When did Clementia Pharmaceuticals IPO?

Clementia Pharmaceuticals (CMTA) raised $101 million in an IPO on Wednesday, August 2nd 2017. The company issued 7,200,000 shares at $13.00-$15.00 per share. Morgan Stanley and Leerink Partners acted as the underwriters for the IPO and Wedbush Securities and BTIG were co-managers.

What other stocks do shareholders of Clementia Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Clementia Pharmaceuticals investors own include Global Blood Therapeutics (GBT), Madrigal Pharmaceuticals (MDGL), Exelixis (EXEL), JPMorgan Chase & Co. (JPM), EyePoint Pharmaceuticals (EYPT), Amicus Therapeutics (FOLD) and MyoKardia (MYOK).

Company Calendar

• Last Earnings: 11/07/2018
• Today: 12/22/2024

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Pharmaceutical Preparations
• Sub-Industry: N/A
• Current Symbol: NASDAQ:CMTA
• CUSIP: N/A
• CIK: 1647320
• Web: www.clementiapharma.com
• Phone: 514-940-3600
• Fax: N/A
• Employees: 30
• Year Founded: N/A

Profitability

• EPS (Most Recent Fiscal Year): ($7.93)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: $-58,130,000.00
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -44.73%
• Return on Assets: -41.66%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 14.03
• Quick Ratio: 14.03

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $5.18 per share
• Price / Book: 5.09

Miscellaneous

• Outstanding Shares: 38,060,000
• Free Float: N/A
• Market Cap: $1.00 billion
• Optionable: Not Optionable
• Beta: 0.64